Skip to main
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 8%
Hold 67%
Sell 25%
Strong Sell 0%

Bulls say

Moderna is projected to experience significant revenue growth, with product sales estimated to rise from $1.73 billion in 2025 to $2.15 billion in 2026, indicating robust demand for its therapeutic offerings. The firm has strengthened its balance sheet through a $1.5 billion debt deal, which enhances its financial flexibility to capitalize on growth opportunities and navigate uncertainties. Additionally, improvements in manufacturing efficiency are expected to expand gross margins by 10% over the next three years, recovering from compressed levels and providing a solid foundation for future profitability.

Bears say

The financial outlook for Moderna appears negative primarily due to declining COVID-19 vaccine sales, which fell from $18 billion in 2022 to $6.7 billion in 2023, alongside reduced revenue guidance for 2025 attributed to waning vaccination rates. Additionally, the competitive landscape for RSV vaccines presents challenges, as approved products like Arexvy and Abrysvo limit the commercial potential of Moderna's mRESVIA. The valuation of Moderna's COVID and COVID+flu vaccine pipeline has decreased from $11.70 billion to $10.50 billion, indicating an overall contraction in expected future revenue, particularly as the pandemic transitions to an endemic phase.

Moderna (MRNA) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 8% recommend Buy, 67% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 12 analysts, Moderna (MRNA) has a Hold consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.